| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Aspirin irreversibly inhibits COX-1 and modifies the enzymatic activity of COX-2. COX-2 normally produces prostanoids, most of which are proinflammatory. -Aspirin irreversibly inhibits the enzyme cyclooxygenase-1 (COX-1). This inhibition reduces the production of thromboxane A₂, a potent promoter of platelet aggregation. -low-dose aspirin is frequently used for the prevention of cardiovascular events such as heart attacks and strokes in individuals at risk. Aspirin (acetylsalicylic acid; ASA) — an acetylating salicylate NSAID that irreversibly inhibits cyclooxygenase (COX) enzymes, producing anti-inflammatory, analgesic/antipyretic, and (at low dose) antiplatelet effects via sustained suppression of platelet thromboxane A₂ (TXA₂). It is a small-molecule oral drug (OTC and prescription formulations; immediate-release and enteric-coated). Standard abbreviations include ASA and “low-dose aspirin” (typically 75–100 mg/day in many guidelines/trials). In cancer biology, the most industry-relevant hypotheses center on platelet COX-1/TXA₂ suppression (metastasis/immune effects) plus COX-2/PGE₂ suppression (inflammatory tumor microenvironment), with clinical signals that are context- and biomarker-dependent. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral absorption is generally rapid (formulation-dependent). Aspirin itself is short-lived in plasma due to rapid deacetylation to salicylate, while platelet COX-1 inhibition persists for the platelet lifespan (functional persistence despite short plasma exposure). Salicylate elimination can become dose-dependent (capacity-limited) at higher doses, extending effective half-life and increasing toxicity/bleeding risk. In-vitro vs systemic exposure relevance: Many anti-proliferative or direct tumor-cell cytotoxic effects reported in vitro occur at concentrations not typically achieved with low-dose antiplatelet regimens; clinically plausible cancer effects at low dose are more consistent with platelet/immune/microenvironment mechanisms than direct tumor cytotoxicity. Clinical evidence status: Strong clinical use exists for antiplatelet indications (cardiovascular secondary prevention and other clinician-directed uses). For primary prevention, contemporary guidance restricts initiation due to bleeding risk (age/risk stratified). For oncology, evidence supports chemopreventive associations (strongest for colorectal cancer in long-term use) and emerging biomarker-stratified adjuvant signals (e.g., PI3K-pathway–altered CRC recurrence reduction in a large randomized setting), but this is not universal across populations and may be age- and context-dependent. **There is debate about the reduced cancer risk effects of aspirin when used long term (10yr). The evidence is stronger for CRC especially for those with IBD. Evidence is more debatable for those 70yrs old. Also there are claims about the anti-Metastasis capabilites of aspirin for those with cancer. Mechanistic and translation-relevant axes for aspirin (ASA) in cancer
TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: TCGA |
| Type: Antiapoptotic |
| Nrf2 is responsible for regulating an extensive panel of antioxidant enzymes involved in the detoxification and elimination of oxidative stress. Thought of as "Master Regulator" of antioxidant response. -One way to estimate Nrf2 induction is through the expression of NQO1. NQO1, the most potent inducer: SFN 0.2 μM, quercetin (2.5 μM), curcumin (2.7 μM), Silymarin (3.6 μM), tamoxifen (5.9 μM), genistein (6.2 μM ), beta-carotene (7.2μM), lutein (17 μM), resveratrol (21 μM), indol-3-carbinol (50 μM), chlorophyll (250 μM), alpha-cryptoxanthin (1.8 mM), and zeaxanthin (2.2 mM) 1. Raising Nrf2 enhances the cell's antioxidant defenses and ↓ROS. This strategy is used to decrease chemo-radio side effects. 2. Downregulating Nrf2 lowers antioxidant defenses and ↑ROS. In cancer cells this leads to DNA damage, and cell death. 3. However there are some cases where increasing Nrf2 paradoxically causes an increase in ROS (cancer cells). Such as cases of Mitochondial overload, signal crosstalk, reductive stress -In some cases, Nrf2 is overexpressed in cancer cells, which can lead to the activation of genes involved in cell proliferation, angiogenesis, and metastasis. This can contribute to the development of resistance to chemotherapy and targeted therapies. -Increased Nrf2 expression: Lung, Breast, Colorectal, Prostrate. Decreased Nrf2 expression: Skine, Liver, Pancreatic. -Nrf2 is a cytoprotective transcription factor which demonstrated both a negative effect as well as a positive effect on cancer - "promotes Nrf2 translocation from the cytoplasm to the nucleus," means facilitates the movement of Nrf2 into the nucleus, thereby enhancing the cell's antioxidant and cytoprotective responses. -Major regulator of Nrf2 activity in cells is the cytosolic inhibitor Keap1. Nrf2 Inhibitors and Activators Nrf2 Inhibitors: Brusatol, Luteolin, Trigonelline, VitC, Retinoic acid, Chrysin Nrf2 Activators: SFN, OPZ EGCG, Resveratrol, DATS, CUR, CDDO, Api - potent Nrf2 inducers from plants include sulforaphane, curcumin, EGCG, resveratrol, caffeic acid phenethyl ester, wasabi, cafestol and kahweol (coffee), cinnamon, ginger, garlic, lycopene, rosemany Nrf2 plays dual roles in that it can protect normal tissues against oxidative damage and can act as an oncogenic protein in tumor tissue. – In healthy tissues, NRF2 activation helps protect cells from oxidative damage and maintains cellular homeostasis. – In many cancers, constitutive activation of NRF2 (often through mutations in NRF2 itself or loss-of-function mutations in KEAP1) leads to an enhanced antioxidant capacity. – This upregulation can promote tumor cell survival by enabling cancer cells to thrive under oxidative stress, resist chemotherapeutic agents, and sustain metabolic reprogramming. – Elevated NRF2 levels have been implicated in promoting tumor growth, metastasis, and resistance to therapy in various malignancies. – High or sustained NRF2 activity is frequently associated with aggressive tumor phenotypes, poorer prognosis, and decreased overall survival in several cancer types. – While its activation is essential for protecting normal cells from oxidative stress, aberrant or sustained NRF2 activation in tumor cells can lead to enhanced survival, therapeutic resistance, and tumor progression. NRF2 inhibitors: (to decrease antioxidant defenses and increase cell death from ROS). -Brusatol: most cited natural inhibitors of Nrf2. -Luteolin: luteolin can reduce Nrf2 activity in specific cancer models and may enhance cell sensitivity to chemotherapy. However, luteolin is also known as an antioxidant, and its influence on Nrf2 can sometimes be context dependent. -Apigenin: certain studies to down‑regulate Nrf2 in cancer cells: Dose and context dependent . -Oridonin: -Wogonin: although its effects might be cell‑ and dose‑specific. - Withaferin A |
| 6538- | MeSal, | ASA, | Salicylate induces AMPK and inhibits c-MYC to activate a NRF2/ARE/miR-34a/b/c cascade resulting in suppression of colorectal cancer metastasis |
| - | in-vitro, | CRC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:1 Target#:226 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid